QURE · uniQure

The thesis

uniQure's Huntington's disease gene therapy, AMT-130, passed the FDA's filing stage with priority review and a decision date of 1 May 2027, but the shares have not recovered: the adjusted close was $22.71 on 10 November 2026, 55.5% below the 52-week high of $51.05. An FDA advisory committee, which the agency is tentatively planning, will decide whether the contested four-year data is enough.

The FDA accepted the biologics license application (BLA) under accelerated approval on 2 November 2026, per the company's release. The filing rests on 36-month data from 12 high-dose patients compared with a propensity score-matched external control. The three-month share price change is −51.7% and the 14-day relative strength index (RSI) is 50.1, down from 62.0 on 28 October 2026 when the close was $24.97.

The story is well known: the filing question that dominated October was answered on 2 November 2026, and attention has moved to the advisory committee and the confirmatory study. Analyst targets set before the acceptance were Barclays' $28 with an Equal-Weight rating (5 October 2026), Goldman Sachs' $31 with Neutral (30 September 2026) and RBC Capital's $48 with Outperform (2 October 2026). No post-acceptance target changes could be verified.

Bullish and bearish views on uniQure N.V.

The bull case on uniQure N.V. (QURE), in brief: the FDA accepted the filing with priority review. The bear case: the headline efficacy measure weakened.

Bull case

• The FDA accepted the filing with priority review. The 2 November 2026 company release sets a PDUFA (Prescription Drug User Fee Act) target action date of 1 May 2027. The product holds Breakthrough Therapy, RMAT and Fast Track designations.
• The agency is reviewing on the three-year analysis. The company said on 17 June 2026 that the FDA would accept the 36-month analysis as the primary basis for an accelerated-approval filing. The 2 November 2026 acceptance confirms that route is proceeding.
• A confirmatory study is agreed. The company and FDA settled on a randomized trial of about 200 patients, 2:1 versus standard of care, with Total Functional Capacity at 36 months as the primary endpoint. Screening is planned to begin by the end of 2026 (Q3 release, 4 November 2026).
• Functional data held at four years. At 48 months, high-dose patients showed 61% slowing on Total Functional Capacity (nominal p=0.008) versus the Enroll-HD B external control (company release, 29 September 2026, data cut 30 June 2026).
• Cash covers the review period. uniQure reported $768.4M in cash, equivalents and investment securities at 30 September 2026, with operations funded into 2030 (Q3 release, 4 November 2026).

Bear case

• The headline efficacy measure weakened. Slowing on the composite Unified Huntington's Disease Rating Scale (cUHDRS) in high-dose patients was 44% at 48 months versus 75% at 36 months, with a nominal p-value of 0.144 (company release, 29 September 2026). The result is not statistically significant.
• An advisory committee adds a public test. The FDA's acceptance letter says it is tentatively planning to discuss the application at an advisory committee, with no date set (company release, 2 November 2026). Panels would examine the external control and the 12-patient dataset.
• The comparison group is contested. uniQure attributes the weaker 48-month result to survivor bias in the updated Enroll-HD B control (company release, 29 September 2026). A result that moves with the choice of control gives reviewers room to discount it.
• Spending is rising before approval. Q3 selling, general and administrative expense was $23.9M versus $19.4M a year earlier, driven by headcount, share-based compensation and launch-related costs. The quarterly net loss was $61.2M, or $0.88 per share (Q3 release, 4 November 2026).
• The company raised equity at higher prices. uniQure priced an upsized $225M offering at $45.50 per share on 24 June 2026, more than double the 10 November 2026 close of $22.71.

Price setup

Adjusted daily closes show $22.71 on 10 November 2026, down from $24.97 on 28 October 2026 and just above the $22.52 close of 15 October 2026. The 52-week high is $51.05. The 14-day RSI of 50.1 sits at the middle of its range, compared with 62.0 on 28 October 2026.

The shares fell over the days around the acceptance news, even though acceptance with priority review was the favorable outcome of the two scheduled events. The market is pricing the advisory committee and the four-year data more than the filing step. No share-short-interest, insider-sale or retail-attention figures were retrieved for this note.

The $20 level is a round figure under the post-data selloff range and below the 15 October 2026 close. A close beneath it would mean the market is pricing a refusal to approve on the existing data.

Catalysts ahead

• 16 November 2026: UBS Global Biopharma Conference, London. A second scheduled platform for management to describe FDA interactions and launch preparation.
• 31 December 2026 (est.): Planned start of US screening for the confirmatory randomized study. Company says screening begins by end of 2026; a slip would show the confirmatory timeline is tighter than stated.
• 1 May 2027: FDA PDUFA target action date for the AMT-130 BLA. The approval decision that settles the thesis; an advisory committee meeting, not yet dated, is expected before it.

Elapsed catalysts

• 11 November 2026: Stifel Healthcare Conference, New York. Management commentary on the advisory committee plan and confirmatory-study timing, ahead of any formal FDA notice. (passed)

What would change the view

A daily close above $30.98, 26% above the last close (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.

What it trades with

The shares trade on the AMT-130 regulatory outcome, so they follow FDA decisions on other gene therapies approved on small or externally controlled datasets. Company news in June 2026 carried reports that the FDA had reversed its rejection of Regenxbio's Navsunli, allowing a refiling, and had scheduled a July advisory committee for Capricor's Deramiocel (Benzinga, 22 June 2026 and 26 June 2026). Biotech funding conditions affect the company less than the regulatory path, because cash of $768.4M at 30 September 2026 is guided to last into 2030.